1. Academic Validation
  2. Dexpramipexole Attenuates White Matter Injury to Facilitate Locomotion and Motor Coordination Recovery via Reducing Ferroptosis after Intracerebral Hemorrhage

Dexpramipexole Attenuates White Matter Injury to Facilitate Locomotion and Motor Coordination Recovery via Reducing Ferroptosis after Intracerebral Hemorrhage

  • Oxid Med Cell Longev. 2022 Aug 4:2022:6160701. doi: 10.1155/2022/6160701.
Bo Wang 1 Xuyang Zhang 1 Jun Zhong 1 Shi Wang 1 Chao Zhang 1 Mingxi Li 2 Quan Hu 3 Shuhong Wang 3 Lin Chen 1 Weixiang Chen 1 4 Hongfei Ge 1 Hua Feng 1
Affiliations

Affiliations

  • 1 Department of Neurosurgery and key Laboratory of Neurotrauma, Southwest Hospital, Third Military Medical University (Army Medical University), 400038 Chongqing, China.
  • 2 Department of Neurosurgery, No. 96603 Unit Hospital of People's Liberation Army of China, 418000 Huaihua, Hunan, China.
  • 3 Department of Emergency, Affiliated Hospital of Zunyi Medical University, 563003 Zunyi, Guizhou, China.
  • 4 Department of Neurosurgery, General Hospital of Xinjiang Military Region, 830000 Urumqi, Xinjiang, China.
Abstract

Deciphering the factors causing damage to white matter fiber bundles and exploring new strategies to alleviate white matter injury (WMI) is a promising treatment to improve neurological impairments after intracerebral hemorrhage (ICH). Ferroptosis usually occurs at perihematomal region and contributes to neuronal death due to Reactive Oxygen Species (ROS) production. Dexpramipexole (DPX) easily crosses the blood brain barrier (BBB) and exerts antioxidative properties by reducing ROS production, while the role of DPX in Ferroptosis after ICH remains elusive. Here, our results indicated that Ferroptosis played a significant role in WMI resulting from iron and ROS accumulation around hematoma. Further evidence demonstrated that the administration of DPX decreased iron and ROS deposition to inhibit Ferroptosis at perihematomal site. With the inhibition of Ferroptosis, WMI was alleviated at perihematomal site, thereafter promoting locomotion and motor coordination recovery in mice after ICH. Subsequently, the results showcased that the expression of Glutathione Peroxidase 4 (GPX4) and Ferroptosis suppressing protein 1 (FSP1) was upregulated with the administration of DPX. Collectively, the present study uncovers the underlying mechanism and elucidates the therapeutic effect of DPX on ICH, and even in Other central nervous system (CNS) diseases with the presence of Ferroptosis.

Figures